Skip to content

ADHD: Gaps Between Patients With Alcohol-dependence and Impact on Relapse

Impact of Attention Deficit/Hyperactivity Disorder on the Post-detoxification Alcohol Relapse Rate

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02364817
Acronym
AGADIR
Enrollment
113
Registered
2015-02-18
Start date
2015-01-31
Completion date
2017-12-31
Last updated
2025-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcoholism, Attention Deficit Disorder With Hyperactivity

Keywords

Attention Deficit Disorder with Hyperactivity, Alcohol Dependence, Adults, Treatment outcome, Mental Health

Brief summary

Some recent studies have found that adult attention deficit - hyperactivity disorder (ADHD) was frequent among patients with alcohol-dependence. However, no investigation has ever addressed whether ADHD may impact the drinking outcome. Moreover, most of the different aforementioned studies assessed ADHD using the ADHD self-report scale (ASRS). The ASRS is a screening questionnaire that is of limited diagnostic value, and the overrepresentation of high-score ASRS among patients with alcohol-dependence could be in part due to differential diagnoses such as antisocial or borderline personality disorders, executive function impairments, or isolated impulsiveness. The study aims to evaluate ADHD: Gaps between patients with Alcohol Dependence and Impact on early Relapse (AGADIR). In AGADIR, subjects with alcohol-dependence are recruited at the end of a residential detoxification program. They are assessed for ADHD using the ASRS, but also with a standardized diagnostic tool, i.e., the Diagnostic Interview for ADHD in adults (DIVA 2.0). Potential differential diagnoses are screened during the baseline visit. The patients are followed-up during the 12 first post-detox weeks, through a standardized psychosocial treatment. ASRS is re-performed at the end of the follow-up.

Interventions

BEHAVIORALcognitive and psychiatric assessment

Administered at baseline: * Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) * hyperactivity : Adult ADHD Self-Report Scale (ASRS), Wenders-Utah Rating Scale (WURS), Diagnostic Interview for Adult ADHD 2nd edition (DIVA 2.0) * psychiatric history : Mini International Neuropsychiatric Interview 5th edition (MINI 5.0), Personality Disorder Questionnaire for the DSM-IV (PDQ-4) * cognitive functions : Frontal Assessment Battery (FAB), Montreal Cognitive Assessment (MoCA) * impulsivity : Barratt's Impulsiveness scale 11th edition (BIS-11) * alcohol consumption: alcohol - timeline follow-back (A-TLFB) ,administered at baseline (month before hospitalization), week 4 visit, week 6 visit, and week 12 visit. * administered at week 12: ASRS

Sponsors

Institute for Scientific Research on Beverages (France)
CollaboratorUNKNOWN
University Hospital, Lille
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* current DSM-IV-Tr criteria for alcohol-dependence * current residential alcohol detoxification program Non-inclusion Criteria: * concurrent alcohol withdrawal symptoms, i.e., CIWA-Ar ≥ 10 * benzodiazepine diazepam-equivalent dose \> 30 mg * medical history of neurological impairment (excluding alcohol-induced cognitive disorders) * guardianship or loss of liberty * pregnant or lactating woman

Design outcomes

Primary

MeasureTime frameDescription
Cumulated rate of alcohol relapse12 weeksCumulated rate of alcohol relapse during the 12 weeks following the detoxification program

Secondary

MeasureTime frameDescription
Psychometric properties of the ASRS12 weeksPsychometric properties of the ASRS by comparison with the DIVA 2.0 and the screening of differential diagnoses
Multivariate analysis of the alcohol relapse12 weeksMultivariate analysis of the cumulated rate of alcohol relapse during the 12 weeks following the detoxification program

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026